Symbols

STRO

Sutro Biopharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About STRO

Sutro Biopharma, Inc.

A clinical-stage oncology company that pioneering site-specific and novel-format antibody drug conjugates

Industry

Pharmaceutical

Established Date

04/21/2003

Listing Date

09/27/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

137

Fiscal Year Ends

12-31

Website

www.sutrobio.com

Security Type

Common stock

Office address

111 Oyster Point Blvd., South San Francisco, California 94080

Business

Introduction

Sutro Biopharma, Inc., was incorporated under the laws of the State of Delaware on April 21, 2003, formerly known as Fundamental Applied Biology, Inc. The Company is a clinical-stage oncology company developing site-specific and novel antibody-drug conjugates through its proprietary integrated cell-free protein synthesis platform XpressCF and site-specific binding platform XpressCF +. The company's goal is to design and develop treatments that use the most relevant and effective models, including ADCs, bispecific ADCs, immunostimulating ADCs or iADCs, bi-conjugate ADCs or ADC2, and cytokine derivatives. The Company's most advanced product candidate is STRO-002, or luveltamab tazevibulin, or luvelta, an ADC targeting folate receptor-α, or FolRα, for cancer patients expressing FolRα, including ovarian cancer.

Company Financials

EPS

STRO has released its 2025 Q4 earnings. EPS was reported at -5.29, versus the expected -8.16, beating expectations. The chart below visualizes how STRO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

STRO has released its 2025 Q4 earnings report, with revenue of 11.65M, reflecting a YoY change of -21.35%, and net profit of -46.76M, showing a YoY change of 35.45%. The Sankey diagram below clearly presents STRO's revenue sources and cost distribution.